The CAR T-Cells Revolution has begun
These past few months, cancer immunotherapy has sped-up thanks to CAR technology. One look at the recent news about this is enough to figure that out. As examples: Two major deals between pharmaceutical companies and biotechs specialized in CAR T-cells: Gilead bought Kite Pharma for $12 billion, and Celgene bought Juno Therapeutics for $9 billion. The Food and […]
